Want to see JP:4506 full AI Analyst Report?
4506 Stock Chart & Stats
¥1284.50
¥16.00(1.25%)
At close: 4:00 PM EDT
¥1284.50
¥16.00(1.25%)
Day’s Range― - ―
52-Week Range¥1,188.00 - ¥3,288.00
Previous CloseN/A
Volume3.36M
Average Volume (3M)5.45M
Market Cap
¥559.84B
Enterprise Value¥737.89K
Total Cash (Recent Filing)¥76.64B
Total Debt (Recent Filing)¥160.66B
Price to Earnings (P/E)4.5
Beta1.37
Next Earnings
Nov 04, 2026EPS Estimate
19.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)279.80
Shares Outstanding449,204,560
10 Day Avg. Volume5,265,230
30 Day Avg. Volume5,454,233
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.82
Price to Sales (P/S)1.82
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,950.00Price Target Upside51.81% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)196.71
Revenue Forecast (FY)¥548.55B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high gross and net margins indicate durable pricing power or favorable product mix in core therapeutic areas. Strong margins provide internal funds for R&D, commercialization and buffer versus reimbursement pressures, improving long-term ability to invest in pipeline and compete globally.
Improved LeverageMaterial reduction in leverage from prior peaks strengthens financial flexibility, lowers refinancing and interest risk, and expands capacity for strategic M&A or co-development deals. A healthier capital structure supports multi-year R&D and commercialization plans without immediate balance-sheet strain.
Positive Free Cash FlowGenerating meaningful free cash flow and cash-to-earnings parity supports sustainable funding for clinical programs, manufacturing scale-up, dividends or debt paydown. Reliable cash conversion underpins long-term capital allocation and reduces reliance on dilutive external financing.
Bears Say
Earnings & Cash VolatilityHistorical swings from deep losses to high profits show the business is exposed to episodic events (one-offs, pipeline readouts, or portfolio shifts). This volatility complicates long-range planning, increases execution risk for multi-year R&D spend and weakens predictability of returns.
Weak OCF Coverage Vs DebtLow operating-cash-to-debt coverage limits the firm's ability to service debt from core operations without asset sales or external financing. This constrains long-term strategic flexibility and raises refinancing and interest-rate sensitivity if cash generation falters.
Revenue Sensitivity To ReimbursementHeavy exposure to Japan's National Health Insurance pricing and reimbursement policies creates structural revenue and margin risk. Regulatory price revisions or reimbursement pressures can materially affect long-term revenue predictability and product economics for marketed drugs.
Sumitomo Dainippon Pharma Co News
4506 FAQ
What was Sumitomo Dainippon Pharma Co Ltd’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co Ltd lowest stock price was ¥1188.00 and its highest was ¥3288.00 in the past 12 months.
What is Sumitomo Dainippon Pharma Co Ltd’s market cap?
Sumitomo Dainippon Pharma Co Ltd’s market cap is ¥559.84B.
When is Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date?
Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date is Nov 04, 2026 which is in 87 days.
How were Sumitomo Dainippon Pharma Co Ltd’s earnings last quarter?
Sumitomo Dainippon Pharma Co Ltd released its earnings results on Jul 31, 2026. The company reported ¥39.02 earnings per share for the quarter, beating the consensus estimate of ¥19.13 by ¥19.89.
Is Sumitomo Dainippon Pharma Co Ltd overvalued?
According to Wall Street analysts Sumitomo Dainippon Pharma Co Ltd’s price is currently Undervalued.
Does Sumitomo Dainippon Pharma Co Ltd pay dividends?
Sumitomo Dainippon Pharma Co Ltd pays a Semiannually dividend of ¥7 which represents an annual dividend yield of N/A. See more information on Sumitomo Dainippon Pharma Co Ltd dividends here
What is Sumitomo Dainippon Pharma Co Ltd’s EPS estimate?
Sumitomo Dainippon Pharma Co Ltd’s EPS estimate is 19.7.
How many shares outstanding does Sumitomo Dainippon Pharma Co Ltd have?
Sumitomo Dainippon Pharma Co Ltd has 449,204,560 shares outstanding.
What happened to Sumitomo Dainippon Pharma Co Ltd’s price movement after its last earnings report?
Sumitomo Dainippon Pharma Co Ltd reported an EPS of ¥39.02 in its last earnings report, beating expectations of ¥19.13. Following the earnings report the stock price went down -3.293%.
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co Ltd?
Currently, no hedge funds are holding shares in JP:4506
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
4506 Company Deck
4506 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted promising developments in the oncology and regenerative medicine pipelines but was overshadowed by significant financial losses, decreased revenue across all segments, and underperformance of key products, leading to a revised downward financial forecast. The call focused on strategic adjustments to address market challenges and improve profitability.View all JP:4506 earnings summaries4506 Stock 12 Month Forecast
Average Price Target
¥1,950.00
▲(51.81% Upside)
Technical Analysis
Eisai Co
―
Kissei Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―